hrp0095p1-108 | Growth and Syndromes | ESPE2022
Efficacy, Observer-Reported Outcomes, and Safety of Once-Weekly Somapacitan in Children with Growth Hormone Deficiency (GHD): 4-Year Results from the REAL 3 Trial
Sävendahl Lars , Battelino Tadej , Højby Rasmussen Michael , Brod Meryl , Wai Lee Kai , Saenger Paul , Horikawa Reiko
hrp0084p1-84 | Growth Hormone | ESPE2015
Brod Meryl , Hojbjerre Lise , Alolga Suzanne , Nacson Alise , Nordholm Lars , Rassmussen Michael Hojby
hrp0084fc7.4 | Growth-promoting therapies | ESPE2015
Zuckerman-Levin Nehama , Gucev Zoran , de Schepper Jean , Rasmussen Michael Hojby , Battelino Tadej , Olsen Minna Braendholt , Savendahl Lars
hrp0095rfc7.2 | Growth and Syndromes | ESPE2022
Once-Weekly Somapacitan vs Daily GH in Children with GH Deficiency: The Randomized Phase 3 REAL 4 Trial
Miller Bradley , Blair Joanne , Højby Michael , Böttcher Volker , Juul Kildemoes Rasmus , Maniatis Aristides , Beck Bang Rikke , Mori Jun , Polak Michel , Stagi Stefano , Horikawa Reiko
hrp0092p1-363 | GH and IGFs (2) | ESPE2019
Damholt Birgitte B , Bjelke Mads , Helleberg Hans , Rasmussen Michael H
hrp0092rfc14.6 | Adrenals and HP Axis | ESPE2019
Brod Meryl , Højby Rasmussen Michael , Vad Knud , Alolga Suzanne , Bedoin Jacques
hrp0092p1-371 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019
Brod Meryl , Rasmussen Michael Højby , Vad Knud , Alolga Suzanne , Bedoin Jacques
hrp0089fc10.2 | Late Breaking | ESPE2018
Savendal Lars , Rasmussen Michael , Horikawa Reiko , Khadilkar Vaman , Battelino Tadej , Saenger Paul
hrp0086p1-p618 | Growth P1 | ESPE2016
Beckert Michael , Gilfoyle David , Mikkelsen Jan Moller , Rasmussen Grethe , Rau Harald , Sprogoe Kennett
hrp0086p2-p671 | Growth P2 | ESPE2016
Brod Meryl , Wilkinson Lars , Alolga Suzanne Lessard , Hojbjerre Lise , Beck Jane , Rasmussen Michael Hojby